CAMBRIDGE, UK & BILLERICA, Mass.--(BUSINESS WIRE)--Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ...
Drug developers are consistently aiming to enhance clinical relevance in drug discovery. CRISPR has emerged as a versatile tool to accelerate the entire drug discovery process, with arrayed CRISPR ...
(Nanowerk Spotlight) For decades, microfluidics has held promise as a revolutionary technology, yet widespread adoption outside research labs has remained elusive. Microfluidic devices enable precise ...
(Nanowerk Spotlight) Microfluidics, the science of manipulating tiny amounts of fluid in micro-scale devices, has long held promise for revolutionizing fields like medical diagnostics, chemistry, and ...
Oak Brook, IL – The February 2023 issue of SLAS Technology contains a set of four original research articles and one review article covering digital microfluidics (DMF), cryopreservation, colorectal ...
CAMBRIDGE, UK & BILLERICA, Mass.--(BUSINESS WIRE)--Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ...
UK-based biotech firm Nuclera has announced it has acquired Taiwan-based E Ink Holdings (EIH)'s digital microfluidics unit to form its US subsidiary. Combining the technologies of the two companies ...
This morning, E Ink announced that their digital microfluidics unit has been acquired by Nuclera, a UK-based biotech company. The acquisition combines the tech of the two companies to create a desktop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results